Actionable news
0
All posts from Actionable news
Actionable news in INCY: Incyte Corporation,

Analysts Take Action on Health Care Stocks

Analysts took action on health care stocks this week.

Incyte Corp. (INCY) has been upgraded by RBC Capital from Sector Perform to a new rating of Outperform, according to a research note dispatched by the analyst on Jan. 2.

This is the first upgrade the stock got over the last four months. During the same period, shares of Incyte Corp. started to be covered by Deutsche Bank with a hold rating and by RBC Capital with a sector perform rating.

BMO Capital maintained its Outperform rating three times on Sept. 11, Oct. 26 and Nov. 1.

Incyte Corp. has a target price of $143.05 per share, which means that analysts on average see a 41.8% upside in the market value of the stock within the next 12 trading months.

Incyte Corp. is currently trading at $100.89 on the Nasdaq stock exchange, with a market capitalization of $21.29 billion. The price-book ratio is 12.09 versus an industry median of 4.10, and the price-sales ratio is 14.36 versus an industry median of 11.76.

For the 52 weeks through Jan. 2, the stock lost 1.4% and underperformed the S&P 500 by 21%. The 52-week range is from $92.91 to $153.15.

According to the Peter Lunch chart, Incyte Corp. is trading below the earnings line without NRI:

The forward price-earnings ratio is 238.10 versus an industry median of 24.21. For full fiscal 2018 analysts forecast Incyte Corp. will report earnings per share of 30 cents, which represents a positive turnaround from a loss of $1.26 as forecasted for full fiscal 2017.

Illumina Inc. (ILMN) got the second upgrade over the last two months as illustrated by Yahoo Finance"s chart. According to a research note dispatched on Jan. 2, shares of Illumina were upgraded to Outperform by Wells Fargo:

Illumina has a target price per share of $225.40 and the recommendation rating is 2 out of 5.

The stock is trading at $224.03 on the Nasdaq stock exchange and has gained nearly 71% over the last 52 weeks, outperforming the S&P 500 which has gained 19.40%. The 52-week range is from $130.25 to $230.72.

Illumina has a market capitalization of $32.71 billion, a price-book ratio of 11.46 versus an industry median of 3.25, a price-sales ratio of 12.74 versus an industry median of 3.36 and a price-earnings ratio of 42.59 versus an industry average of 31.08.

The forward price-earnings ratio is 50 and for full fiscal 2018, analysts forecast earnings per share of $4.48.

On Jan. 2, Bank of America upgraded shares of Medtronic PLC (MDT) from neutral to buy. On Dec. 12, the stock was also upgraded by Argus to buy from a previous hold rating.


More